GSK-J1

Ligand id: 7027

Name: GSK-J1

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 7
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 91.24
Molecular weight 389.19
XLogP 5.08
No. Lipinski's rules broken 1

Molecular properties generated using the CDK

Classification
Compound class Synthetic organic
Prodrug GSK-J4
IUPAC Name
3-{[2-(pyridin-2-yl)-6-(2,3,4,5-tetrahydro-1H-3-benzazepin-3-yl)pyrimidin-4-yl]amino}propanoic acid
Database Links
CAS Registry No. 1373422-53-7 (source: Scifinder)
ChEMBL Ligand CHEMBL3188597
PubChem CID 56963315
RCSB PDB Ligand K0I, URY
Search Google for chemical match using the InChIKey AVZCPICCWKMZDT-UHFFFAOYSA-N
Search Google for chemicals with the same backbone AVZCPICCWKMZDT
Search UniChem for chemical match using the InChIKey AVZCPICCWKMZDT-UHFFFAOYSA-N
Search UniChem for chemicals with the same backbone AVZCPICCWKMZDT
SynPHARM 83291 (in complex with lysine demethylase 5B)
Comments
GSK-J1 is a catalytic site inhibitor that is somewhat selective for the H3K27me3-specific demethylases KDM6A and 6B (a.k.a. UTX and JMJD3 respectively) [2]. The compund has also been shown to inhibit H3K4me3/me2 catalysed by KDM5 enzymes in vitro [1].
This is a compound from the Structural Genomics Consortium's (SGC) Epigenetics Probes Collection. It reduces lipopolysaccharide-induced proinflammatory cytokine production by human primary macrophages, a process that depends on both JMJD3 and UTX.